A recent study found that thinking about bigger meals can actually cut back on snacking.

Published Date: 08 Mar 2023

The so-called "meal reminder effect" can reduce the amount of food a person eats later. Researchers from the University of Cambridge studied the impact of emotions on mindful eating.

Read Full News

Latest News

Study shows Ozempic could help dialysis patients qualify for kidney transplants

Obesity is one of the biggest barriers preventing patients with end-stage kidney disease from receiving a life-saving kidney transplant. New research from Saint Louis University School of Medicine and SSM Health physicians ...

How do I know if my kid is worrying about food and their body too much? And what should I say?

Eating disorders are most likely to develop in young people aged between 12 and 25.

Understudied eating disorder matches anorexia, bulimia severity

A diagnosis often viewed as less serious than anorexia and bulimia—and the most common eating disorder worldwide—can cause just as much harm, a new study has found.

Popular weight-loss drugs show added heart protection for diabetes patients

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this ...

Diabetes drug reduced irregular heartbeat events in overweight/obese adults with AFib

People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science ...

Mandatory nutrient warning labels could prevent 100,000+ obesity-related deaths

Researchers from the University of Liverpool have found that making front-of-pack nutrition labeling mandatory could significantly reduce obesity rates and save thousands of lives across England.

Todays Updates

Lacosamide Displays Positive Efficacy and Safety in Phase 2 Clinical Trial of Neonatal Seizures Louie Pasculli

Findings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.

This Week on NeurologyLive® — December 8, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

GABA-AT Inhibitor OV329 Shows Safety, Preliminary Target Engagement in Phase 1 Study Marco Meglio

Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

5 Pulmonology Headlines You Missed in November 2025

5 Pulmonology Headlines You Missed in November 2025

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Stage 5 CKD May Reverse Female Survival Advantage

Stage 5 CKD May Reverse Female Survival Advantage

Todays Updates

Lacosamide Displays Positive Efficacy and Safety in Phase 2 Clinical Trial of Neonatal Seizures Louie Pasculli

Findings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.

This Week on NeurologyLive® — December 8, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

GABA-AT Inhibitor OV329 Shows Safety, Preliminary Target Engagement in Phase 1 Study Marco Meglio

Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.

Microbiota Restoration Therapy: A New Era in C. difficile Management, With Paul Feuerstadt, MD Paul Feuerstadt, MD

FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.

5 Pulmonology Headlines You Missed in November 2025

5 Pulmonology Headlines You Missed in November 2025

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Stage 5 CKD May Reverse Female Survival Advantage

Stage 5 CKD May Reverse Female Survival Advantage

Latest News

Obesity is one of the biggest barriers preventing patients with end-stage kidney disease from receiving a life-saving kidney transplant. New research from Saint Louis University School of Medicine and SSM Health physicians ...

Eating disorders are most likely to develop in young people aged between 12 and 25.

A diagnosis often viewed as less serious than anorexia and bulimia—and the most common eating disorder worldwide—can cause just as much harm, a new study has found.

Injectable weight-loss drugs can reduce the risk of serious cardiovascular events for people with type 2 diabetes. Researchers at the Technical University of Munich (TUM) and Harvard Medical School have demonstrated this ...

People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science ...

Researchers from the University of Liverpool have found that making front-of-pack nutrition labeling mandatory could significantly reduce obesity rates and save thousands of lives across England.

News All Time

Five reasons we shouldn't 'compliment' people who lose weight

"You look so great! Have you lost weight?"

Nearly 70% of US adults meet new definition of obesity, study finds

The prevalence of obesity in the United States could rise sharply under a definition of obesity released earlier this year by the Lancet Diabetes and Endocrinology Commission.

BMI shouldn't be the only way to assess who can access weight-loss drugs

About 1 in 3 Australian adults (32%) has a body-mass index (BMI) of 30 or above. A further 34% has a BMI of 25 or above.

Diets high in ultra-processed foods are bad for us, so why are we eating more?

Aussies eat more ultra-processed foods than ever before, with busy lifestyles and personal choices often taking the blame as casual factors.

Weight loss drug stigma shows society still holds negative attitudes towards body weight and obesity

Since Wegovy received approval as a weight loss treatment in 2021, there has been huge demand for GLP-1 drugs. These drugs reduce hunger and suppress the "food noise" that can make it difficult to lose weight.

Two in three people with chronic pain turn to comfort eating

More than two-thirds of people living with chronic pain reach for chocolate or other comfort foods to cope, with new research showing that eating offers pleasure, distraction and relief from negative emotions during pain ...

Gaps and opportunities in precision medicine approach to obesity treatment identified

A new report led by researchers at Pennington Biomedical Research Center underscores the growing potential of precision medicine to transform how obesity is prevented, diagnosed and treated, while also illuminating key gaps ...

Think your BMI reflects your health? Think again, study warns

As new Statistics Canada data reveals that two-thirds of Canadians are considered overweight or obese, researchers are urging the public and policymakers to rethink how we define and measure health—starting with one of ...

Use of weight loss drugs before bariatric surgery has soared in recent years, study finds

New research findings show a significant increase in the use of weight loss drugs among patients undergoing metabolic and bariatric surgery, signaling an evolution in the management of obesity and type 2 diabetes.

Research highlights the need for culturally specific screening tools

Despite research finding a higher prevalence of eating disorders among Aboriginal youth in Australia, new research from Edith Cowan University (ECU) published in the Journal of Eating Disorders has revealed a lack of culturally ...

Semaglutide, tirzepatide recommended as first-line treatment of obesity and most of its complications in new guidance

Semaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new framework for the pharmacological treatment of obesity and its complications from ...

Weight-loss surgery could help boost work productivity

A new international QUT-led study found that bariatric surgery improves work productivity and employment rates in the short term—but these gains may not last beyond five years without targeted support.

Reducing risk of eating disorders by controlling peer and family pressures

Weight-related peer teasing is a strong predictor of disordered eating behaviors in adolescents, particularly those at higher genetic risk, new research shows.

Study suggests new drug for weight loss may cause fewer side effects

A new Penn Nursing study suggests that the weight-loss drug tirzepatide may cause fewer side effects like nausea and vomiting than the drug semaglutide. This research, published in Science Advances, was conducted using preclinical ...

Weight loss treatments for people with diabetes and obesity could lower the risk of obesity-related cancers

Weight loss treatments, including medication and surgical procedures, may help lower the risk of obesity-related cancers in people with obesity and type 2 diabetes, a new study shows.

Too heavy for medical care: Over 40% of specialty clinics turn away patients weighing 465 pounds

Patients weighing 450 pounds or more face barriers and discrimination when scheduling or attending doctor visits at subspecialty practices, reports a new Northwestern Medicine study.

Recommended News For You

Why preventive mastectomy isn't offered to everyone at risk

Healthcare in the Mix in President Biden's Farewell Address

tobacco use, the severity of their symptoms, and their desire to give up smoking among cancer survivors.

Risk of a second cancer after early breast cancer is low, say new findings

When does a melanoma metastasize? Implications for management

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

Nirogacestat is approved by the FDA for treating rare non-cancerous soft tissue sarcomas.

Recommended Articles For You

Emerging and Innovative Therapies in Cancer Treatment and Post-Surgical Care 

Uncovering the Mystery of Burkitt's Lymphoma: A New Hope for Treatment 

Next-Gen CAR Cell Therapies in Oncology: Frontiers in Solid Tumors & Hematologic Malignancies 

Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance

2.

PET-CT is better than contrast-enhanced CT as a predictor of survival in patients with metastatic breast cancer

3.

Clinical trial is testing whether heavy lifting could combat cancer side effects

4.

Scientists are investigating the prevention of recurrent breast cancer, which frequently results in death.

5.

Cancer cells with thick glycocalyx barrier evade immune system better: study

1.

Unlocking the Mystery of Basilar Artery Stroke: A New Approach to Treatment

2.

The Importance of Early Detection in Skin Cancer: Why Regular Skin Exams Matter 

3.

AI and Optical Advances: Evolving Blood Cell Morphology Observation in Hematology

4.

The New Era of Oncology: Key Updates and Clinical Insights

5.

Examining Serum Osmolality: What It Is And How To Test For It

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII

2.

Learning About Different Treatment Approaches For Acute Lymphoblastic Leukemia

3.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part I

4.

Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC

5.

Efficient Management of First line ALK-rearranged NSCLC - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot